Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELE | P16581 | 14/20 | 0.46 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.34 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.32 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.32 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.32 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21993232 | 0.92 | SELE (0.46) | SELEADAMTS5ADAMTS4CA1CA2 | |
| SCHEMBL24092200 | 0.87 | SELE (0.58) | SELE | |
| SCHEMBL21993228 | 0.87 | SELE (0.50) | SELEADAMTS5ADAMTS4CA1CA2 | |
| SCHEMBL24489403 | 0.87 | SELE (0.58) | SELE | |
| SCHEMBL24092201 | 0.87 | SELE (0.58) | SELE | |
| SCHEMBL24092205 | 0.87 | SELE (0.41) | SELEADAMTS5ADAMTS4CA1CA2 | |
| SCHEMBL21992408 | 0.86 | SELE (0.46) | SELEADAMTS5ADAMTS4CA1CA2 | |
| SCHEMBL21992409 | 0.81 | SELE (0.50) | SELEADAMTS5ADAMTS4CA1CA2 | |
| SCHEMBL24092214 | 0.81 | SELE (0.58) | SELE | |
| SCHEMBL24489201 | 0.80 | SELE (0.52) | SELE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220175808-A1 | GALACTOPYRANOSYL-CYCLOHEXYL DERIVATIVES AS E-SELECTIN ANTAGONISTS | GLYCOMIMETICS, INC. (US) | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175808-A1 | GALACTOPYRANOSYL-CYCLOHEXYL DERIVATIVES AS E-SELECTIN ANTAGONISTS | SELE, SELPLG, SELP | SELE 1/4885ADAMTS5 1099/4885ADAMTS4 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.